Share Price and Basic Stock Data
Last Updated: January 20, 2026, 10:36 pm
| PEG Ratio | 2.62 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Acutaas Chemicals Ltd, operating in the pharmaceuticals sector, reported a current price of ₹1,710 and a market capitalization of ₹14,000 Cr. The company has demonstrated a robust upward trajectory in revenue, with sales increasing from ₹520 Cr in FY 2022 to ₹1,007 Cr in FY 2025. This represents a compound annual growth rate (CAGR) of approximately 25.3% over the three-year period. Quarterly sales figures reflect this trend, with a notable rise from ₹147 Cr in September 2022 to ₹225 Cr in March 2024. The trailing twelve months (TTM) sales stood at ₹1,097 Cr, indicating a strong performance that positions Acutaas favorably against industry peers. The steady increase in sales underlines the company’s ability to capitalize on market opportunities and expand its product offerings, contributing to its overall growth strategy.
Profitability and Efficiency Metrics
Acutaas Chemicals Ltd recorded a net profit of ₹224 Cr in the TTM, translating to an impressive net profit margin of 15.93%. The company’s operating profit margin (OPM) also showed significant improvement, rising to 24.73% in FY 2025 from 20% in FY 2023. This increase in profitability is supported by a reduction in expenses, which grew at a slower pace than sales, reflecting operational efficiency. The interest coverage ratio stood at 40.04x, indicating strong earnings relative to interest obligations, and suggesting a low financial risk. Furthermore, the return on equity (ROE) at 16% and return on capital employed (ROCE) at 19.9% demonstrate effective capital utilization. While the OPM is higher than the typical sector average, the fluctuations in quarterly performance, particularly the dip to 14% in September 2023, raise questions about consistency.
Balance Sheet Strength and Financial Ratios
The financial health of Acutaas Chemicals Ltd is underscored by its strong balance sheet, with total assets reported at ₹1,696 Cr and minimal borrowings of ₹8 Cr. The company’s reserves increased significantly to ₹1,373 Cr by September 2025, reflecting a strong retained earnings position. The current ratio was reported at 3.91, indicating ample liquidity to meet short-term obligations, while the quick ratio stood at 3.02, suggesting that the company can cover its liabilities without relying on inventory sales. The price-to-book value ratio at 7.63x is elevated compared to typical industry values, indicating that the stock may be overvalued relative to its net assets. In terms of debt management, Acutaas has maintained a very low total debt-to-equity ratio of 0.01, showcasing a conservative approach to leverage.
Shareholding Pattern and Investor Confidence
As of September 2025, Acutaas Chemicals Ltd had a diverse shareholding structure, with promoters holding 32.66%, foreign institutional investors (FIIs) at 16.84%, domestic institutional investors (DIIs) at 22.59%, and the public accounting for 27.89%. This distribution indicates a balanced mix of institutional and retail investment, contributing to a stable investor base. Notably, the promoter shareholding has declined from 39.41% in December 2022 to the current level, which may reflect a dilution strategy to enhance liquidity or attract additional institutional investment. The increase in FII and DII holdings over time suggests growing confidence in the company’s growth prospects. The number of shareholders rose to 1,08,664, indicating rising retail interest, which can positively affect liquidity and market perception.
Outlook, Risks, and Final Insight
Looking ahead, Acutaas Chemicals Ltd appears well-positioned for continued growth, driven by its expanding sales and strong profitability metrics. However, risks remain, particularly related to operational consistency, as evidenced by the volatility in quarterly profit margins. Furthermore, the high price-to-book ratio raises concerns about valuation sustainability amid market fluctuations. The company must navigate competitive pressures within the pharmaceuticals sector while maintaining operational efficiency to sustain its profitability. Additionally, potential regulatory changes could impact operational dynamics. Overall, while the company’s fundamentals are robust, it must address these risks to foster long-term shareholder value and market confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 120 Cr. | 95.1 | 205/84.3 | 26.5 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,638 Cr. | 334 | 479/192 | 75.4 | 24.3 | 0.20 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.2 Cr. | 43.4 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.7 Cr. | 40.1 | 41.0/17.0 | 140 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,513.32 Cr | 1,087.69 | 50.89 | 202.18 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 147 | 152 | 186 | 154 | 172 | 166 | 225 | 177 | 247 | 275 | 308 | 207 | 306 |
| Expenses | 119 | 122 | 146 | 120 | 148 | 140 | 182 | 147 | 198 | 206 | 224 | 156 | 211 |
| Operating Profit | 28 | 31 | 41 | 34 | 25 | 27 | 43 | 30 | 49 | 69 | 85 | 51 | 95 |
| OPM % | 19% | 20% | 22% | 22% | 14% | 16% | 19% | 17% | 20% | 25% | 28% | 25% | 31% |
| Other Income | 1 | 3 | -0 | 1 | -30 | 3 | 1 | 1 | 8 | 2 | 6 | 16 | 10 |
| Interest | 0 | 1 | 1 | 1 | 1 | 3 | 2 | 4 | 0 | 1 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 3 | 4 | 4 | 4 | 5 | 6 | 7 | 6 | 7 | 8 | 8 |
| Profit before tax | 26 | 30 | 37 | 31 | -10 | 24 | 37 | 20 | 50 | 63 | 83 | 58 | 96 |
| Tax % | 26% | 25% | 26% | 28% | 71% | 25% | 31% | 26% | 25% | 28% | 24% | 24% | 25% |
| Net Profit | 19 | 22 | 27 | 22 | -17 | 18 | 26 | 15 | 38 | 45 | 63 | 44 | 72 |
| EPS in Rs | 2.61 | 3.06 | 3.73 | 2.71 | -2.55 | 2.27 | 3.41 | 1.71 | 4.56 | 5.49 | 7.63 | 5.41 | 8.82 |
Last Updated: December 28, 2025, 5:00 am
Below is a detailed analysis of the quarterly data for Acutaas Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 306.00 Cr.. The value appears strong and on an upward trend. It has increased from 207.00 Cr. (Jun 2025) to 306.00 Cr., marking an increase of 99.00 Cr..
- For Expenses, as of Sep 2025, the value is 211.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 156.00 Cr. (Jun 2025) to 211.00 Cr., marking an increase of 55.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 95.00 Cr.. The value appears strong and on an upward trend. It has increased from 51.00 Cr. (Jun 2025) to 95.00 Cr., marking an increase of 44.00 Cr..
- For OPM %, as of Sep 2025, the value is 31.00%. The value appears strong and on an upward trend. It has increased from 25.00% (Jun 2025) to 31.00%, marking an increase of 6.00%.
- For Other Income, as of Sep 2025, the value is 10.00 Cr.. The value appears to be declining and may need further review. It has decreased from 16.00 Cr. (Jun 2025) to 10.00 Cr., marking a decrease of 6.00 Cr..
- For Interest, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 8.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 8.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 96.00 Cr.. The value appears strong and on an upward trend. It has increased from 58.00 Cr. (Jun 2025) to 96.00 Cr., marking an increase of 38.00 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Jun 2025) to 25.00%, marking an increase of 1.00%.
- For Net Profit, as of Sep 2025, the value is 72.00 Cr.. The value appears strong and on an upward trend. It has increased from 44.00 Cr. (Jun 2025) to 72.00 Cr., marking an increase of 28.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 8.82. The value appears strong and on an upward trend. It has increased from 5.41 (Jun 2025) to 8.82, marking an increase of 3.41.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:15 am
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 160 | 188 | 239 | 240 | 341 | 520 | 617 | 717 | 1,007 | 1,097 |
| Expenses | 137 | 157 | 196 | 198 | 260 | 415 | 493 | 589 | 775 | 797 |
| Operating Profit | 23 | 31 | 42 | 42 | 80 | 105 | 123 | 128 | 232 | 300 |
| OPM % | 14% | 16% | 18% | 17% | 24% | 20% | 20% | 18% | 23% | 27% |
| Other Income | 0 | 3 | 0 | 2 | 1 | 3 | 4 | -25 | 17 | 33 |
| Interest | 3 | 3 | 5 | 6 | 6 | 6 | 2 | 6 | 6 | 3 |
| Depreciation | 1 | 2 | 3 | 4 | 4 | 10 | 12 | 16 | 27 | 30 |
| Profit before tax | 19 | 28 | 35 | 35 | 72 | 91 | 112 | 82 | 216 | 300 |
| Tax % | 35% | 35% | 34% | 21% | 25% | 21% | 26% | 41% | 26% | |
| Net Profit | 12 | 18 | 23 | 27 | 54 | 72 | 83 | 49 | 160 | 224 |
| EPS in Rs | 40.17 | 61.67 | 11.10 | 13.08 | 8.57 | 9.87 | 11.43 | 5.80 | 19.38 | 27.35 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 15% | 13% | 26% | 8% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 50.00% | 27.78% | 17.39% | 100.00% | 33.33% | 15.28% | -40.96% | 226.53% |
| Change in YoY Net Profit Growth (%) | 0.00% | -22.22% | -10.39% | 82.61% | -66.67% | -18.06% | -56.24% | 267.49% |
Acutaas Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 33% |
| 3 Years: | 25% |
| TTM: | 40% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 41% |
| 3 Years: | 30% |
| TTM: | 205% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 39% |
| 1 Year: | 97% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 14% |
| Last Year: | 16% |
Last Updated: September 5, 2025, 2:16 pm
Balance Sheet
Last Updated: December 4, 2025, 2:21 am
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 10 | 10 | 32 | 36 | 36 | 37 | 41 | 41 |
| Reserves | 37 | 56 | 72 | 101 | 135 | 486 | 558 | 637 | 1,269 | 1,373 |
| Borrowings | 27 | 44 | 54 | 59 | 137 | 1 | 4 | 217 | 13 | 8 |
| Other Liabilities | 43 | 54 | 77 | 61 | 110 | 136 | 169 | 205 | 227 | 274 |
| Total Liabilities | 109 | 155 | 213 | 232 | 413 | 659 | 767 | 1,096 | 1,549 | 1,696 |
| Fixed Assets | 28 | 32 | 79 | 85 | 186 | 205 | 259 | 427 | 570 | 700 |
| CWIP | 11 | 30 | 2 | 12 | 0 | 3 | 30 | 125 | 130 | 152 |
| Investments | 1 | 3 | 2 | 2 | 1 | 2 | 2 | 0 | 0 | 0 |
| Other Assets | 68 | 91 | 131 | 133 | 225 | 450 | 477 | 543 | 848 | 843 |
| Total Assets | 109 | 155 | 213 | 232 | 413 | 659 | 767 | 1,096 | 1,549 | 1,696 |
Below is a detailed analysis of the balance sheet data for Acutaas Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 41.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 41.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,373.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,269.00 Cr. (Mar 2025) to 1,373.00 Cr., marking an increase of 104.00 Cr..
- For Borrowings, as of Sep 2025, the value is 8.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 13.00 Cr. (Mar 2025) to 8.00 Cr., marking a decrease of 5.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 274.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 227.00 Cr. (Mar 2025) to 274.00 Cr., marking an increase of 47.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,696.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,549.00 Cr. (Mar 2025) to 1,696.00 Cr., marking an increase of 147.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 700.00 Cr.. The value appears strong and on an upward trend. It has increased from 570.00 Cr. (Mar 2025) to 700.00 Cr., marking an increase of 130.00 Cr..
- For CWIP, as of Sep 2025, the value is 152.00 Cr.. The value appears strong and on an upward trend. It has increased from 130.00 Cr. (Mar 2025) to 152.00 Cr., marking an increase of 22.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 843.00 Cr.. The value appears to be declining and may need further review. It has decreased from 848.00 Cr. (Mar 2025) to 843.00 Cr., marking a decrease of 5.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,696.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,549.00 Cr. (Mar 2025) to 1,696.00 Cr., marking an increase of 147.00 Cr..
Notably, the Reserves (1,373.00 Cr.) exceed the Borrowings (8.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -4.00 | -13.00 | -12.00 | -17.00 | -57.00 | 104.00 | 119.00 | -89.00 | 219.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 83 | 97 | 116 | 86 | 129 | 115 | 136 | 105 | 105 |
| Inventory Days | 76 | 89 | 95 | 148 | 123 | 150 | 131 | 139 | 119 |
| Days Payable | 148 | 154 | 168 | 146 | 172 | 158 | 157 | 119 | 103 |
| Cash Conversion Cycle | 11 | 31 | 43 | 88 | 80 | 107 | 111 | 125 | 121 |
| Working Capital Days | 46 | 64 | 28 | 34 | 51 | 141 | 139 | 79 | 123 |
| ROCE % | 38% | 34% | 27% | 33% | 24% | 21% | 16% | 20% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Large & Midcap Fund | 2,000,000 | 0.99 | 367.5 | 2,275,837 | 2025-11-02 14:30:42 | -12.12% |
| Kotak Multicap Fund | 1,366,139 | 1.13 | 251.03 | N/A | N/A | N/A |
| SBI Healthcare Opportunities Fund | 900,000 | 4 | 165.38 | 1,000,000 | 2025-11-02 14:30:42 | -10% |
| UTI Small Cap Fund | 524,144 | 1.99 | 96.31 | 592,983 | 2025-11-02 14:30:42 | -11.61% |
| ITI Small Cap Fund | 453,450 | 2.96 | 83.32 | 446,344 | 2025-11-02 14:30:42 | 1.59% |
| Tata ELSS Fund | 434,420 | 1.66 | 79.82 | N/A | N/A | N/A |
| Kotak Balanced Advantage Fund | 390,000 | 0.4 | 71.66 | N/A | N/A | N/A |
| Union Small Cap Fund | 360,154 | 3.72 | 66.18 | 350,154 | 2025-11-02 14:30:42 | 2.86% |
| Bank of India Small Cap Fund | 353,000 | 3.27 | 64.86 | 373,610 | 2025-12-14 01:12:31 | -5.52% |
| Bank of India Flexi Cap Fund | 329,922 | 2.69 | 60.62 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 19.81 | 11.67 | 22.86 | 21.03 | 17.14 |
| Diluted EPS (Rs.) | 19.81 | 11.66 | 22.86 | 21.03 | 17.14 |
| Cash EPS (Rs.) | 45.69 | 17.56 | 26.25 | 22.51 | 18.47 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 319.93 | 185.13 | 163.01 | 143.34 | 52.99 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 319.93 | 185.13 | 163.01 | 143.34 | 52.99 |
| Revenue From Operations / Share (Rs.) | 245.97 | 194.54 | 169.26 | 142.75 | 108.13 |
| PBDIT / Share (Rs.) | 60.83 | 36.87 | 34.83 | 29.62 | 25.88 |
| PBIT / Share (Rs.) | 54.33 | 32.52 | 31.45 | 26.86 | 24.55 |
| PBT / Share (Rs.) | 52.81 | 22.21 | 30.79 | 25.10 | 22.77 |
| Net Profit / Share (Rs.) | 39.19 | 13.21 | 22.86 | 19.75 | 17.14 |
| NP After MI And SOA / Share (Rs.) | 38.77 | 11.60 | 22.86 | 19.75 | 17.14 |
| PBDIT Margin (%) | 24.73 | 18.95 | 20.58 | 20.75 | 23.93 |
| PBIT Margin (%) | 22.08 | 16.71 | 18.57 | 18.81 | 22.70 |
| PBT Margin (%) | 21.46 | 11.41 | 18.18 | 17.58 | 21.05 |
| Net Profit Margin (%) | 15.93 | 6.78 | 13.50 | 13.83 | 15.85 |
| NP After MI And SOA Margin (%) | 15.76 | 5.96 | 13.50 | 13.83 | 15.85 |
| Return on Networth / Equity (%) | 12.11 | 6.34 | 14.02 | 13.77 | 32.34 |
| Return on Capital Employeed (%) | 16.50 | 14.79 | 18.96 | 18.47 | 31.28 |
| Return On Assets (%) | 10.24 | 3.90 | 10.86 | 10.91 | 13.06 |
| Long Term Debt / Equity (X) | 0.00 | 0.16 | 0.00 | 0.00 | 0.43 |
| Total Debt / Equity (X) | 0.01 | 0.32 | 0.01 | 0.00 | 0.70 |
| Asset Turnover Ratio (%) | 0.76 | 0.77 | 0.86 | 0.97 | 1.06 |
| Current Ratio (X) | 3.91 | 1.74 | 2.89 | 3.32 | 1.30 |
| Quick Ratio (X) | 3.02 | 1.19 | 2.15 | 2.45 | 0.93 |
| Inventory Turnover Ratio (X) | 5.98 | 3.19 | 2.99 | 3.27 | 3.10 |
| Dividend Payout Ratio (NP) (%) | 7.73 | 25.55 | 13.12 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 6.62 | 18.58 | 11.43 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 92.27 | 74.45 | 86.88 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 93.38 | 81.42 | 88.57 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 40.04 | 22.89 | 52.62 | 16.85 | 14.51 |
| Interest Coverage Ratio (Post Tax) (X) | 26.80 | 14.60 | 35.53 | 12.23 | 10.61 |
| Enterprise Value (Cr.) | 9764.07 | 4208.12 | 3184.01 | 3543.73 | 0.00 |
| EV / Net Operating Revenue (X) | 9.70 | 5.87 | 5.16 | 6.81 | 0.00 |
| EV / EBITDA (X) | 39.21 | 30.95 | 25.09 | 32.83 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 9.93 | 5.63 | 5.25 | 7.00 | 0.00 |
| Retention Ratios (%) | 92.26 | 74.44 | 86.87 | 0.00 | 0.00 |
| Price / BV (X) | 7.63 | 5.99 | 5.45 | 6.97 | 0.00 |
| Price / Net Operating Revenue (X) | 9.93 | 5.63 | 5.25 | 7.00 | 0.00 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.01 | 0.00 |
After reviewing the key financial ratios for Acutaas Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 19.81. This value is within the healthy range. It has increased from 11.67 (Mar 24) to 19.81, marking an increase of 8.14.
- For Diluted EPS (Rs.), as of Mar 25, the value is 19.81. This value is within the healthy range. It has increased from 11.66 (Mar 24) to 19.81, marking an increase of 8.15.
- For Cash EPS (Rs.), as of Mar 25, the value is 45.69. This value is within the healthy range. It has increased from 17.56 (Mar 24) to 45.69, marking an increase of 28.13.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 319.93. It has increased from 185.13 (Mar 24) to 319.93, marking an increase of 134.80.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 319.93. It has increased from 185.13 (Mar 24) to 319.93, marking an increase of 134.80.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 245.97. It has increased from 194.54 (Mar 24) to 245.97, marking an increase of 51.43.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 60.83. This value is within the healthy range. It has increased from 36.87 (Mar 24) to 60.83, marking an increase of 23.96.
- For PBIT / Share (Rs.), as of Mar 25, the value is 54.33. This value is within the healthy range. It has increased from 32.52 (Mar 24) to 54.33, marking an increase of 21.81.
- For PBT / Share (Rs.), as of Mar 25, the value is 52.81. This value is within the healthy range. It has increased from 22.21 (Mar 24) to 52.81, marking an increase of 30.60.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 39.19. This value is within the healthy range. It has increased from 13.21 (Mar 24) to 39.19, marking an increase of 25.98.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 38.77. This value is within the healthy range. It has increased from 11.60 (Mar 24) to 38.77, marking an increase of 27.17.
- For PBDIT Margin (%), as of Mar 25, the value is 24.73. This value is within the healthy range. It has increased from 18.95 (Mar 24) to 24.73, marking an increase of 5.78.
- For PBIT Margin (%), as of Mar 25, the value is 22.08. This value exceeds the healthy maximum of 20. It has increased from 16.71 (Mar 24) to 22.08, marking an increase of 5.37.
- For PBT Margin (%), as of Mar 25, the value is 21.46. This value is within the healthy range. It has increased from 11.41 (Mar 24) to 21.46, marking an increase of 10.05.
- For Net Profit Margin (%), as of Mar 25, the value is 15.93. This value exceeds the healthy maximum of 10. It has increased from 6.78 (Mar 24) to 15.93, marking an increase of 9.15.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 15.76. This value is within the healthy range. It has increased from 5.96 (Mar 24) to 15.76, marking an increase of 9.80.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.11. This value is below the healthy minimum of 15. It has increased from 6.34 (Mar 24) to 12.11, marking an increase of 5.77.
- For Return on Capital Employeed (%), as of Mar 25, the value is 16.50. This value is within the healthy range. It has increased from 14.79 (Mar 24) to 16.50, marking an increase of 1.71.
- For Return On Assets (%), as of Mar 25, the value is 10.24. This value is within the healthy range. It has increased from 3.90 (Mar 24) to 10.24, marking an increase of 6.34.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.16 (Mar 24) to 0.00, marking a decrease of 0.16.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has decreased from 0.32 (Mar 24) to 0.01, marking a decrease of 0.31.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.76. It has decreased from 0.77 (Mar 24) to 0.76, marking a decrease of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 3.91. This value exceeds the healthy maximum of 3. It has increased from 1.74 (Mar 24) to 3.91, marking an increase of 2.17.
- For Quick Ratio (X), as of Mar 25, the value is 3.02. This value exceeds the healthy maximum of 2. It has increased from 1.19 (Mar 24) to 3.02, marking an increase of 1.83.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.98. This value is within the healthy range. It has increased from 3.19 (Mar 24) to 5.98, marking an increase of 2.79.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 7.73. This value is below the healthy minimum of 20. It has decreased from 25.55 (Mar 24) to 7.73, marking a decrease of 17.82.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.62. This value is below the healthy minimum of 20. It has decreased from 18.58 (Mar 24) to 6.62, marking a decrease of 11.96.
- For Earning Retention Ratio (%), as of Mar 25, the value is 92.27. This value exceeds the healthy maximum of 70. It has increased from 74.45 (Mar 24) to 92.27, marking an increase of 17.82.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.38. This value exceeds the healthy maximum of 70. It has increased from 81.42 (Mar 24) to 93.38, marking an increase of 11.96.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 40.04. This value is within the healthy range. It has increased from 22.89 (Mar 24) to 40.04, marking an increase of 17.15.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 26.80. This value is within the healthy range. It has increased from 14.60 (Mar 24) to 26.80, marking an increase of 12.20.
- For Enterprise Value (Cr.), as of Mar 25, the value is 9,764.07. It has increased from 4,208.12 (Mar 24) to 9,764.07, marking an increase of 5,555.95.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 9.70. This value exceeds the healthy maximum of 3. It has increased from 5.87 (Mar 24) to 9.70, marking an increase of 3.83.
- For EV / EBITDA (X), as of Mar 25, the value is 39.21. This value exceeds the healthy maximum of 15. It has increased from 30.95 (Mar 24) to 39.21, marking an increase of 8.26.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 9.93. This value exceeds the healthy maximum of 3. It has increased from 5.63 (Mar 24) to 9.93, marking an increase of 4.30.
- For Retention Ratios (%), as of Mar 25, the value is 92.26. This value exceeds the healthy maximum of 70. It has increased from 74.44 (Mar 24) to 92.26, marking an increase of 17.82.
- For Price / BV (X), as of Mar 25, the value is 7.63. This value exceeds the healthy maximum of 3. It has increased from 5.99 (Mar 24) to 7.63, marking an increase of 1.64.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 9.93. This value exceeds the healthy maximum of 3. It has increased from 5.63 (Mar 24) to 9.93, marking an increase of 4.30.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Acutaas Chemicals Ltd:
- Net Profit Margin: 15.93%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 16.5% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.11% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 26.8
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.02
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 59.3 (Industry average Stock P/E: 50.89)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 15.93%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No. 440/4, 5 & 6, Surat Gujarat 394230 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Nareshkumar Ramjibhai Patel | Exe.Chairman & Mng.Director |
| Mr. Virendra Nath Mishra | Whole Time Director |
| Mr. Ram Mohan Rao Locande | Whole Time Director |
| Mr. Chetankumar Chhaganlal Vaghasia | Whole Time Director |
| Mr. Hetal Madhukant Gandhi | Independent Director |
| Mr. Girikrishna Suryakant Maniar | Independent Director |
| Mrs. Richa Manoj Goyal | Independent Director |
| Dr. Anita Bandyopadhyay | Independent Director |
FAQ
What is the intrinsic value of Acutaas Chemicals Ltd?
Acutaas Chemicals Ltd's intrinsic value (as of 20 January 2026) is ₹1611.50 which is 0.89% lower the current market price of ₹1,626.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹13,285 Cr. market cap, FY2025-2026 high/low of ₹1,902/919, reserves of ₹1,373 Cr, and liabilities of ₹1,696 Cr.
What is the Market Cap of Acutaas Chemicals Ltd?
The Market Cap of Acutaas Chemicals Ltd is 13,285 Cr..
What is the current Stock Price of Acutaas Chemicals Ltd as on 20 January 2026?
The current stock price of Acutaas Chemicals Ltd as on 20 January 2026 is ₹1,626.
What is the High / Low of Acutaas Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Acutaas Chemicals Ltd stocks is ₹1,902/919.
What is the Stock P/E of Acutaas Chemicals Ltd?
The Stock P/E of Acutaas Chemicals Ltd is 59.3.
What is the Book Value of Acutaas Chemicals Ltd?
The Book Value of Acutaas Chemicals Ltd is 173.
What is the Dividend Yield of Acutaas Chemicals Ltd?
The Dividend Yield of Acutaas Chemicals Ltd is 0.09 %.
What is the ROCE of Acutaas Chemicals Ltd?
The ROCE of Acutaas Chemicals Ltd is 19.9 %.
What is the ROE of Acutaas Chemicals Ltd?
The ROE of Acutaas Chemicals Ltd is 16.0 %.
What is the Face Value of Acutaas Chemicals Ltd?
The Face Value of Acutaas Chemicals Ltd is 5.00.